Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026)
Maze Therapeutics (MAZE) reported Return on Capital Employed of 34.62% for Q1 2026, down 5335.0% on a YoY basis from 0.66% in Q1 2025, and up 6.23% sequentially from 36.92% in Q4 2025.
Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of Return on Capital Employed data on file, last reported at 34.62% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 5335.0% year-over-year to 34.62%; the trailing twelve-month figure through Mar 2026 stood at 34.62% (down 5335.0% YoY), and the FY2025 full-year result was 48.23%, changed N/A from the prior year.
- Return on Capital Employed rose to 34.62% in Q1 2026, from 36.92% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 18.73% in Q1 2025 to a low of 42.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | -34.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.62% |
| Dec 31, 2025 | -36.92% |
| Sep 30, 2025 | -39.50% |
| Jun 30, 2025 | -42.19% |
| Mar 31, 2025 | 18.73% |